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Abstract 
Monoclonal antibodies are used to detect serum antigens associated 
with malignancies. The tumor markers are most useful for 
monitoring response to therapy and detecting early relapse. Tumor 
markers are special molecules released by tumor cells, found in high 
levels in patients with malignancies. Each tumor marker is organ 
specific and is elevated in specific type of malignancy and its level in 
circulating blood provide a clue about the type and severity of the 
disease. The blood level is very useful for diagnosis, prognosis and 
to check recurrence after treatment. Experiments were performed to 
investigate and establish if there are any associations between the 
principle tumor markers viz CEA (colon caner) , CA125 (ovarian 
cancer) and CA15.3 (breast cancer) to the diagnostically useful 
macro-metals Calcium and Magnesium and to suggest if the above 
two metals need to be analyzed along with the tumor markers for 
the diagnostic purposes. The study was done with the blood serum 
sample of suspected or established cancer patients (both men and 
women). For the samples, biochemical assay using electro-
chemiluminescence technique (for CEA, CA 125 and CA 15.3) was 
used; Calcium and Magnesium were analyzed using manual dye-
binding methods and the readings were acquired using a semi auto 
analyzer. Appropriate statistical methods were used to conclude 
that, there exists a very strong relationship between CA 125 and CA 
15.3; and proved that CA 15.3 is linked to both metals Calcium and 
Magnesium; whereas CEA shows an inverse correlation with CA 125. 
 
Introduction 
In recent years, laboratory diagnosis has achieved a prominent place 
in medical services and hence lab services form an integral part of 
the health care delivery. 
In this study, an attempt has been made to investigate and establish 
if there are any associations between the principle tumour markers 
viz., CEA, CA125 and CA15.3 to the diagnostically useful macro-
metals Calcium and Magnesium and to suggest if the above two 
metals need to be analyzed along with the tumor markers for the 
diagnostic purposes. 
Review 
Monoclonal antibodies are used to detect serum antigens associated 
with malignancies. The tumor markers are most useful for 
monitoring response to therapy and detecting early relapse.  
Tumor markers are special molecules released by tumor cells; found 
in high levels in patients with malignancies. Each tumor marker is 
organ specific and is elevated in specific type of malignancy and its 
level in circulating blood provide a clue about the type and severity 
of the disease. The blood level is very useful for diagnosis, prognosis 
and to check recurrence after treatment. For example prostrate 
specific antigen (PSA) is a very specific and useful screening test for 
prostrate cancer and to monitor the response to treatment. The 
blood level correlates well with Digital Rectal Examination (DRE). 
The ideal marker for the purpose of diagnosis would have two 
characteristics: 1) it would be secreted into the blood in measurable 
concentration only after the cells that produced it has undergone 
malignant transformation and 2) detection of it would permit 
conclusion as to the site of tumor from which it arose. The use of 
diagnostic tests in the clinical setting is highly controlled by 
regulatory bodies, but Tumor Markers have been particularly 
identified for special consideration.  
Carcinoembryonic antigen (Cea) 
CEA, an oncofetal glycoprotein, is expressed in normal mucosal cells 
and over expressed in adeno carcinoma, especially colorectal cancer. 
CEA elevation also occurs with other malignancies. CEA is not useful 
in the screening of colorectal cancer. This test should be ordered 
only after malignancy has been confirmed. CEA levels typically 
return to normal within 4 to 6 weeks after successful surgical 
resection. 
Cancer antigen 125 (CA 125) 
CA125 is a glycoprotein normally expressed in coelomic epithelium 
during fetal development. This epithelium lines body cavities and 
envelopes the ovaries.Elevated CA125 values most often are 
associated with epithelial ovarian, although levels also can be 
decreased in other malignancies. CA125 levels are elevated in about 
85% of women with ovarian cancer, but in only 50% of those with 
stage 1 disease. Multiple benign disorders also are associated with 
CA125 elevations, presumably by stimulation of the serosal surfaces. 
Cancer antigen 15.3 (CA 15.3) 
CA 15-3 is a high molecular weight ( 300 to 450 kDa) polymorphic 
epithelial mucin, also known as breast cancer mucin, that is 
produced by many cancers of the breast.  It is not used for 
screening, but is recommended as a follow up after breast cancer 
has been treated. In some cases it will allow a relapse to be 
detected before becoming clinically apparent. CA15-3 is not elevated 
during pregnancy. The percentage of raised values found in breast 
cancer can be as high as 98%, but this depends primarily on the 
tumor stage of the patient population studied. Elevated levels have 
also been found in patients with lung cancer (63%) and ovarian 
cancer (80%). 
Calcium and cancer 
Experts say excessive calcium intake may be unwise in light of 
recent studies showing that high amounts of the mineral may 
increase risk of prostate cancer. “There is reasonable evidence to 
suggest that calcium may play an important role in the development 
of prostate cancer,” says Dr. Carmen Rodriguez, senior 
epidemiologist in the epidemiology and surveillance research 
department of the American Cancer Society (ACS). 
The adverse effects of excessive calcium intake may include high 
blood calcium levels, kidney stone formation and kidney 
complications. Elevated calcium levels are also associated with 
arthritic/joint and vascular degeneration, calcification of soft tissue, 
hypertension and stroke, and increase in VLDL triglycerides, 
gastrointestinal disturbances, mood and depressive disorders, 
chronic fatigue, and general mineral imbalances including 
magnesium, zinc, iron and phosphorus. High calcium levels interfere 
with Vitamin D and subsequently inhibit the vitamin’s cancer 
protective effect unless extra amounts of Vitamin D are 
supplemented. 
Magnesium and cancer 
One of the first organs to calcify is the ovaries leading to pre-
menstrual syndrome. High magnesium diet has reversed the above 
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status. There is no substitute for magnesium in human physiology; 
nothing comes even close to it in terms of its effect on overall cell 
physiology. Without sufficient magnesium, the body accumulates 
toxins and acid residues, degenerates rapidly, and ages prematurely. 
It goes against a gale wind of medical science to ignore magnesium 
chloride used transdermally in the treatment of any chronic or acute 
disorder, especially cancer. Early signs of magnesium deficiency are, 
loss of appetite, nausea, vomiting, fatigue and weakness. Increased 
deficiency may show as numbness, fingling, muscle contractions and 
cramps, seizures, personality change, abnormal heart rhythms and 
coronary spasms. Severe deficiency results with hypocalcemia and 
hypokalemia.Magnesium have a calming effect on the nervous 
system and are frequently used to promote good sleep. It can be 
used to calm irritated and over excited nerves. Epilepsy is marked by 
abnormally low levels of magnesium in blood. 
Materials and Method 
After completely going through the literature review where Calcium 
and Magnesium, are cited either as causative factor in inducing 
cancer of a particular type by its deficiency or accumulation, we 
decided to select a reasonable number (n=64) of suspected or 
established cancer patients to evaluate if any association exist 
between the type of cancer and the individual metals. 
Subjects 
64 patients comprising of both male and female in the age group of 
14 to 79 who reported to the out patient clinic for cancer related 
symptoms (routine screening as well as established cancer patients) 
were enrolled for the study. As the laboratory has recently 
established normal values for 3 tumor markers and 2 metals for 
which we wanted to evaluate association, we directly estimated 
those parameters for the purpose of finding an association. The 
subjects selected consisted of 39 females in the age group of 14 to 
71 years and 25 males in the age group of 24 to 79 years. In order 
to cover our study for a wide range of age and sex related subjects. 
Sample collection 
As tumor markers and metals do not vary due to fasting or non-
fasting status, sample collection was done between 9-10.30 am for 
all the patients. Exact sample collection procedures were followed, 
such as use of sterile and disposable needles and vaccutainer for 
collecting the samples. Qualified phlebotomist was used in all blood 
collection in order to prevent pre-analytical errors that may be 
carried to the assay stage. This includes a correct site of vein 
puncture and the pressure used to transfer the blood into the 
vaccutainer. 
Sample processing 
All the blood samples were allowed to clot at room temperature for 
30 minutes, the tubes were gently tapped to displace clot adhering 
to the tube and then centrifuged with the cap on in each tube for 10 
minutes at 2500 rpm. Serum from each tube was transferred to 
another set of appropriate labeled tubes using disposable plastic 
dropping pipettes. The samples were either analyzed immediately or 





Using the latest electro-chemiluminiscent analyzer, (Updated version 
of Enzyme Immuno Assay), used for the assay of Hormones, Tumor 
Markers and Drugs, 3 tumor markers (CEA, CA 125 and CA 15.3) 
were estimated. Extensive quality control measures were done so as 
to get accurate values. 
For measuring Calcium and Magnesium, manual dye-binding 
methods were used and the readings were acquired using a semi 
auto analyzer. 
Results and Discussion 
Table 1 shows the results obtained for all the patients, for the 3 
tumor markers and 2 metals (Calcium and Magnesium) along with 
their ratio. As CA 125 and CA 15.3 refers only to the female 
patients, it is hence not presented for the male patients. The mean 
and the Standard Deviation for the same are given in this table 
along with its normal range. 
It is clearly seen from the Table that, the mean values for the tests 
CA125 and CA 15.3 are highly elevated. This is due to the fact that, 
a few patients had values in the abnormal range, which contributed 
for the higher Mean and Standard Deviation. CA 15.3 too is on the 
upper limit, while, Calcium mean value is on the lower limit of the 
normal range and Magnesium is on the median level. 
We neither have selected a separate control group, nor chose 
established cancer patients, but have randomly selected, patients 
who attended the Cancer Screening Program, at our Oncology 
Department. 
From the individual values obtained, we can see that, the majority of 
the patient values are within the normal range. 
Since the sole aim of the study was to establish a relationship 
between the 3 tumor markers namely (CEA, CA125 and CA15.3), 
and the macro-metals (Calcium and Magnesium), we have presented 
all the data together in a single Table. 
As the mean age of all the patients is 54, the age at which many 
people attend the cancer screening program, justifies that our study 
was done using patients attending cancer program. 
Since CA 125 and CA 15.3 are tumor markers related to females, the 
same was not carried out for the male population. Table 2 presents 
similar data for 39 females out of 64 total patients. Just like Table 1, 
the mean age for female patients is calculated to be 53. CA 125 and 
CA 15.3 were analyzed for all 39 patients whereas CEA was done for 
27 patients. The CEA analysis was stopped with 27 in Table 2 since 
the total CEA samples analyzed exceeded the initial plan of 50 (Total 
CEA analyzed was 52). The mean values in Table 2, for the markers 
CEA and CA125, are very high because, a few patient samples 
recorded abnormal values. The mean value of CA 15.3 is close to the 
upper limit. As observed in Table 1, mean Calcium is at the lower limit 
and mean Magnesium is at the median range. Table 3 represents data 
for CEA, Calcium, Magnesium, and the ratio between Calcium and 
Magnesium for 25 Male patients.  Here, the mean Age is similar to 
that in Table 1 and 2. Mean CEA was found to be twice the Upper 
Limit and both Calcium and Magnesium are close to the normal range. 
Since the mean Calcium and Magnesium values are similar to the 
values followed in the Clinical Laboratory, we envisage that there may 
not be any significant correlation if subjected to statistical analysis.
 
Table 1 – All patients 
 
S.no Age Sex CEA CA 125 CA 15.3 Ca Mg Ca/Mg 
1 50 F 3.7 7927 93.7 9 2.21 4.07 
2 59 M 1.7   9.4 1.85 5.08 
3 64 M 2.3   9.6 1.94 4.94 
4 55 M 5.1   9.4 1.94 4.84 
5 54 F 1.1 65.3 37.56 9.8 1.82 5.38 
6 57 M 1.9   9.5 1.86 5.1 
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7 79 M 3.2   9.5 2.06 4.61 
8 74 M 2.6   10.3 1.79 5.75 
9 24 M 4.8   9.4 2.26 4.15 
10 66 M 1   9.3 2.2 4.22 
11 45 F 0.7 119 8.1 7.3 2.23 3.27 
12 49 F 105 25 18.92 9.4 1.87 5.52 
13 74 M 7   11 2.06 5.33 
14 56 M 58   9.4 1.9 4.94 
15 54 M 1   9.5 1.78 5.33 
16 60 M 2.9   13.1 2.02 6.48 
17 71 F 3.3 8 15.72 9.3 2.6 3.57 
18 48 M 6.1   8.7 1.78 4.88 
19 43 F 3.76 19.92 14.35 9.3 2.08 4.47 
20 53 M 4.2   8.7 2.1 4.14 
21 75 M 11.2   9.7 1.65 5.87 
22 32 F 1.53 40.7 11.18 8.9 1.67 5.32 
23 60 M 2.5   8.9 1.91 4.65 
24 56 M 2.6   9.6 2.5 3.84 
25 48 F 4.42 13.83 14.91 8.8 2.03 4.33 
26 50 M 4.7   8.8 2.22 3.96 
27 14 F 1.22 15.44 9.27 9.1 1.92 4.73 
28 48 F 2.09 14.23 11.95 8.9 1.61 5.52 
29 65 F 167.5 1.09 10.4 9.3 1.87 4.97 
30 68 F 0.775 35.04 6.7 8.7 2.1 4.14 
31 63 F 6.11 14 29 8.1 2.09 3.87 
32 46 F 0.6 38 19 8.6 2.3 3.73 
33 65 F 2 6.56 11 8.6 1.78 4.83 
34 67 F 2 456.7 17 7.9 1.84 4.29 
35 56 F 1.96 1078 86 7 2.52 2.77 
36 66 F 3 19 9 8.7 1.93 4.5 
37 60 M 1.9   8.8 2.48 3.54 
38 50 F 1.9 6 21.57 9.7 1.68 6.06 
39 57 M 8   10.4 1.8 5.77 
40 43 F 2.36 10 12.31 9.5 1.88 5.05 
41 47 M 3   9.5 1.73 5.49 
42 41 M 1.8   10.1 1.81 5.58 
43 47 F 3.88 13.48 24.31 9.6 2.01 4.77 
44 60 F 1.76 7 13.88 9 1.44 6.25 
45 29 M 0.2   10 2.29 4.36 
46 57 M 14   9.6 1.95 4.92 
47 58 F 0.5 6 12.9 9.1 1.7 5.35 
48 53 M 11.1   8.1 1.93 4.19 
49 63 F 1.8 8.32 21.99 8.5 1.66 5.12 
50 55 F 65 114.7 79.42 8.4 2.11 3.98 
51 54 F 3 9 17.48 9.7 2.14 4.53 
52 62 F 14.4 22.77 24.04 10.1 2 5.05 
53 52 F  249 84 7.2 1.72 4.18 
54 60 F  348.4 19 9.5 1.44 6.59 
55 52 F  16 23 9.7 1.66 5.84 
56 40 F  16 13 9.6 1.77 5.42 
57 69 F  1106 77 9.2 1.913 4.8 
58 43 F  63 31 8.7 1.7 5.11 
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59 46 F  11 21 10.1 1.92 5.26 
60 57 F  82.5 31 8,6 2.25 3.82 
61 44 F  103 46 9.4 1.61 5.83 
62 71 F  6 21 8.8 1.92 4.58 
63 52 F  15.7 8.3 9.6 1.52 6.31 
64 40 F  29 14.2 10.3 2.16 4.76 
 
 
 Age CEA CA 125 CA 15.3 Ca Mg Ca/Mg 
Mean 54.32 10.92 311.27 26.67 9.24 1.94 4.84 
Standard 
Deviation 
12.14 28.55 1276.28 23.85 0.88 0.26 0.8 
Normal Range  <3.0 <35 <40 8.4 – 10.2 1.6 – 2.3  
 
Table 2- Female patients 
 
S.no Age Sex CEA CA 125 CA 15.3 Ca Mg Ca/Mg 
1 50 F 3.7 7927 93.7 9 2.21 4.07 
2 54 F 1.1 65.3 37.56 9.8 1.82 5.38 
3 45 F 0.7 119 8.1 7.3 2.23 3.27 
4 49 F 105 25 18.92 9.4 1.87 5.52 
5 71 F 3.3 8 15.72 9.3 2.6 3.57 
6 43 F 3.76 19.92 14.35 9.3 2.08 4.47 
7 32 F 1.53 40.7 11.18 8.9 1.67 5.32 
8 48 F 4.42 13.83 14.91 8.8 2.03 4.33 
9 14 F 1.22 15.44 9.27 9.1 1.92 4.73 
10 48 F 2.09 14.23 11.95 8.9 1.61 5.52 
11 65 F 167.5 1.09 10.4 9.3 1.87 4.97 
12 68 F 0.775 35.04 6.7 8.7 2.1 4.14 
13 63 F 6.11 14 29 8.1 2.09 3.87 
14 46 F 0.6 38 19 8.6 2.3 3.73 
15 65 F 2 6.56 11 8.6 1.78 4.83 
16 67 F 2 456.7 17 7.9 1.84 4.29 
17 56 F 1.96 1078 86 7 2.52 2.77 
18 66 F 3 19 9 8.7 1.93 4.5 
19 50 F 1.9 6 21.57 9.7 1.68 6.06 
20 43 F 2.36 10 12.31 9.5 1.88 5.05 
21 47 F 3.88 13.48 24.31 9.6 2.01 4.77 
22 60 F 1.76 7 13.88 9 1.44 6.25 
23 58 F 0.5 6 12.9 9.1 1.7 5.35 
24 63 F 1.8 8.32 21.99 8.5 1.66 5.12 
25 55 F 65 114.7 79.42 8.4 2.11 3.98 
26 54 F 3 9 17.48 9.7 2.14 4.53 
27 62 F 14.4 22.77 24.04 10.1 2 5.05 
28 52 F  249 84 7.2 1.72 4.18 
29 60 F  348.4 19 9.5 1.44 6.59 
30 52 F  16 23 9.7 1.66 5.84 
31 40 F  16 13 9.6 1.77 5.42 
32 69 F  1106 77 9.2 1.913 4.8 
33 43 F  63 31 8.7 1.7 5.11 
34 46 F  11 21 10.1 1.92 5.26 
35 57 F  82.5 31 8,6 2.25 3.82 
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36 44 F  103 46 9.4 1.61 5.83 
37 71 F  6 21 8.8 1.92 4.58 
38 52 F  15.7  9.6 1.52 6.31 
39 40 F  29  10.3 2.16 4.76 
 
Table 3 - Male patients 
 
 Age CEA CA125 CA15.3 Ca Mg Ca/Mg 
Mean 
53.026 15.014 311.27 26.671 9.0105 1.9147 4.819 
Standard Deviation 
11.679 38.026 1276.3 23.852 0.7693 0.2705 0.858 
Normal Range  






 S. no. 
  Age  Sex  CEA  Ca  Mg 
 Ca/
Mg 
 1  59  M  1.7  9.4  1.85  5.08 
 2  64  M  2.3  9.6  1.94  4.94 
 3  55  M  5.1  9.4  1.94  4.84 
 4  57  M  1.9  9.5  1.86  5.1 
 5  79  M  3.2  9.5  2.06  4.61 
 6  74  M  2.6  10.3  1.79  5.75 
 7  24  M  4.8  9.4  2.26  4.15 
 8  66  M  1  9.3  2.2  4.22 
 9  74  M  7  11  2.06  5.33 
 10  56  M  58  9.4  1.9  4.94 
 11  54  M  1  9.5  1.78  5.33 
 12  60  M  2.9  13.1  2.02  6.48 
 13  48  M  6.1  8.7  1.78  4.88 
 14  53  M  4.2  8.7  2.1  4.14 
 15  75  M  11.2  9.7  1.65  5.87 
 16  60  M  2.5  8.9  1.91  4.65 
 17  56  M  2.6  9.6  2.5  3.84 
 18  50  M  4.7  8.8  2.22  3.96 
 19  60  M  1.9  8.8  2.48  3.54 
 20  57  M  8  10.4  1.8  5.77 
 21  47  M  3  9.5  1.73  5.49 
 22  41  M  1.8  10.1  1.81  5.58 
 23  29  M  0.2  10  2.29  4.36 
 24  57  M  14  9.6  1.95  4.92 
 25  53  M  11.1  8.1  1.93  4.19 
   Age  CEA  Ca  Mg  Ca/Mg 
 Mean  56.32  6.51  9.61  1.99  4.87 
 Standard 
Deviation 
 12.81  11.28  0.95  0.22  0.71 











Table 4- All patients 
 
S.no Pairs compared R t p 
 
1 CEA Vs CA 125 -0.35924 -2.34 0.0124 
 
2 CA 125 Vs Mg 0.21261 1.32 0.0969 
 
3 CA 125 Vs CA 15.3 0.57099 4.23 <.0001 
 
4 CA 15.3 Vs Ca -0.35924 -2.34 0.0124 
 
5 CA 15.3 Mg 0.21262 1.32 0.0969 
 




Table 5- Female patients 
 
S.no Pairs compared R t p 
1 CA 125 Vs Mg 0.21262 1.32 0.0969 
2 CA 125 Vs CA 15.3 0.57099 4.23 <.0001 
3 CA 15.3 Vs Ca -0.35924 -2.34 0.0124 
4 CA 15.3 Mg 0.21262 1.32 0.0969 




Statistical analysis of data 
Table 4 gives the statistical parameters ie, Correlation co-efficient 
(r), Students Distribution (t) and probability (p), for the three tumor 
markers compared in pairs. Only CA 125 and CA 15.3 comparison to 
the metals and the ratio of the metals are presented in this Table, 
since no correlation was obtained when compared CEA with either 
Calcium or Magnesium.It is interesting to observe from this table 
that, there is a strong relationship between CA 125 and CA 15.3 (r= 
0.57099; t= 4.23; p= <0.001), suggesting that, while screening for 
tumors in female in one organ, it is important to estimate the 
markers for the other. CA 15.3 shows inverse correlation to both 
Calcium and the ratio between Calcium and Magnesium (P= >0.05), 
thereby linking CA 15.3 to both metals. As CA 125 and CA 15.3 
shows excellent correlation, CA 125 too must be associated with 
Magnesium. One interesting observation is that, while CEA as 
presented in Table 3, did not show any correlation to any of the 
metals, it gives an inverse correlation with CA 125. As CA 125 is 
correlated to both metals, CEA too should have an association to the 
metals thereby linking all the three tumor markers to the macro 
metals. Table 5 presents similar data to that of Table 4, except that, 
it is for female patients. This table does not contain CEA contrary to 
the one seen in Table 4. This suggests that the circulating levels in 
female patients may not have association to the Metals. The 
statistical parameters (r; t; and p) obtained for female group is 
almost similar to the one in Table 4. Hence the outcome is almost as 
described for Table 4. 
Conclusion 
Previous studies have established the importance of both Calcium 
and Magnesium in almost all types of Cancer. Both Hypocalcemia 
and Hypomagnesemia, were observed in critically ill cancer patients 
and Magnesium deficiency can directly lead to Cancer. Our study 
although did not establish the above statements, we have found out 
the association between the tumor markers present in a specific 
cancer and the metals Calcium and Magnesium. Since the population 
selected were from Oncology Clinic, the mean values for Calcium 
and Magnesium were at the lower end while, the tumour marker 
values were at the higher end. This suggests that, in established 
Cancer patients, the two metal concentrations may be lower as 
found in majority of the previous studies. Many western studies, 
unlike the Indian literature, have many data, linking Cancer Antigens 
to Metals. It is time that the medical profession start using 
Magnesium as a primary treatment tool, since it is very difficult to 
find cancer patients with normal levels of Calcium and Magnesium. 
Our findings too are consistent with the pervious observations. A 
recent article on Cancer and Magnesium predict that 46% of all 
Cancer patients admitted to ICU were presented with Hypocalcaemia 
and Hypomagnesaemia and our study partially established this 
observation. As the number of male patients are only 25, were 
unable to establish a direct relationship between CEA and the 
metals, but its relationship with metals were linked by CA 125, 
thereby bringing into the picture, the association between CEA and 
the metals. 
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